HLA-G and graft versus host disease: Recently, other strategies are being tested to generate allogeneic CAR T cells as an off-the-shelf product, mostly by knocking out the gene encoding TCR and/or disrupting HLA molecules (β2-microglobulin) on donor T cells to prevent the GVHD and/or the transplant rejection, showing encouraging response with no GVHD (21).